Lv6
2414 积分 2022-10-24 加入
Discovery of Clinical Candidate IAG933, a Potent YAP-TEAD PPI Disrupter
24天前
已完结
515LBA (PB-515) LBA Posters: CID-078, a first-in-class oral macrocycle cyclin A/B-RxL inhibitor, demonstrates anti-tumor activity in E2F-driven cancers
1个月前
已完结
Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design
1个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1个月前
已完结
Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin’s Interactions with Its Nuclear Partners
1个月前
已完结
Discovery, Optimization, and Preclinical Pharmacology of EP652, a METTL3 Inhibitor with Efficacy in Liquid and Solid Tumor Models
1个月前
已完结
From Transient to Stable: Incorporating Electrophiles in Genetically-Encoded and DNA-Encoded Libraries of Peptide-Derived Macrocycles
2个月前
已完结
A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors
2个月前
已完结
Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development
2个月前
已完结
Covalent and Noncovalent Targeting of the Tcf4/β-Catenin Strand Interface with β-Hairpin Mimics
2个月前
已完结
皖公网安备34019202002308
